Øystein
Bruserud
Professor
Visit Address:
Haukeland universitetssykehus, Laboratoriebygget
5021 Bergen
Postal Address:
Postboks 7804
5021 Bergen
Phone:
+47 55 97 29 97
E-mail:
Books
- 2009. Medikamentell kreftbehandling. Cytostikaboken. Cytokiner i kreftbehandlingen. 495 pages. ISBN: 978-829923312-5.
Journal articles
- 2014. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer. 13. doi: 10.1186/1476-4598-13-116
- 2014. Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia? Expert opinion on therapeutic targets. 18: 929-944. doi: 10.1517/14728222.2014.924925
- 2014. Heat shock protein 90 – a potential target in the treatment of human acute myelogenous leukemia. Advances in cancer drug targets. 2: 3-53. doi: 10.2174/9781608059386114020003
- 2014. Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. British Journal of Haematology. 164: 200-211. doi: 10.1111/bjh.12611
- 2013. CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia. OncoTarget. 4: 1438-1448.
- 2013. Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacology & Toxicolog. 14. 13 pages. doi: 10.1186/2050-6511-14-35
- 2013. Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfusion Medicine. 23: 397-406. doi: 10.1111/tme.12067
- 2013. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics. 5:13. doi: 10.1186/1868-7083-5-13
- 2013. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical Epigenetics. 5:12. doi: 10.1186/1868-7083-5-12
- 2013. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death & Disease. 4. doi: 10.1038/cddis.2013.39
- 2013. Primær myelofibrose – patogenese, diagnostikk og behandling. Tidsskrift for Den norske legeforening. 133: 1946-1950. doi: 10.4045/tidsskr.12.1106
- 2013. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 121: E34-E42. doi: 10.1182/blood-2012-05-429555
- 2013. Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma. Cytotherapy. 15: 850-860. doi: 10.1016/j.jcyt.2013.02.008
- 2013. Iodinin (1,6-dihydroxyphenazine 5,10-dioxide) from streptosporangium sp. induces apoptosis selectively in myeloid leukemia cell lines and patient cells. Marine Drugs. 11: 332-349. Published 2013-01-30. doi: 10.3390/md11020332
- 2013. The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine-the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. Toxins. 5: 336-362. doi: 10.3390/toxins5020336
- 2013. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Current Cancer Drug Targets. 13: 30-47. doi: 10.2174/1568009611309010030
- 2013. Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells. OncoTarget. 4: 830-843.
- 2013. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opinion on Investigational Drugs. 22: 551-563. doi: 10.1517/13543784.2013.791280
- 2013. Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients. Cell Proliferation. 46: 554-562. doi: 10.1111/cpr.12057
- 2013. Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients. Oncoimmunology. 2. 11 pages. doi: 10.4161/onci.23138
- 2013. The role of arginine and arginine-metabolizing enzymes during Giardia – host cell interactions in vitro. BMC Microbiology. 13. Published 2013-11-14. doi: 10.1186/1471-2180-13-256
- 2012. High-dose etoposide in allogeneic stem cell transplantation. Cancer Chemotherapy and Pharmacology. 70: 765-782. doi: 10.1007/s00280-012-1990-z
- 2012. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. American Journal of Hematology. 87: 368-376. doi: 10.1002/ajh.23116
- 2012. Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. European Journal of Haematology. 89: 478-490. doi: 10.1111/ejh.12016
- 2012. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling. Blood. 120: 847-857. doi: 10.1182/blood-2011-10-388496
- 2012. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 26: 910-917. doi: 10.1038/leu.2011.315
- 2012. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology. 156: 468-480. doi: 10.1111/j.1365-2141.2011.08960.x
- 2012. The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. European Cytokine Network. 23: 140-153. doi: 10.1684/ecn.2012.0322
- 2012. The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications. Biology of blood and marrow transplantation. 18: 190-199. doi: 10.1016/j.bbmt.2011.10.007
- 2012. Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia? Expert Opinion on Investigational Drugs. 21: 587-603. doi: 10.1517/13543784.2012.668525
- 2012. The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status. Leukemia. 26: 557-559. doi: 10.1038/leu.2011.243
- 2012. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 31: 1533-1545. doi: 10.1038/onc.2011.348
- 2011. Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma. Cytotherapy. 13: 1259-1268. doi: 10.3109/14653249.2011.605117
- 2011. Is there a scientific basis for a recommended standardization of collection and cryopreservation of peripheral blood stem cell grafts? Cytotherapy. 13: 1013-1024. doi: 10.3109/14653249.2011.574117
- 2011. Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia. Blood reviews. 25: 113-122. doi: 10.1016/j.blre.2011.01.006
- 2011. A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. European Cytokine Network. 22: 52-62. doi: 10.1684/ecn.2011.0271
- 2011. Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia-Targeting of disease heterogeneity through direct and indirect antileukemic effects. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 35: 1156-1158. doi: 10.1016/j.leukres.2011.06.005
- 2011. Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies. Bone Marrow Research. 2011.
- 2011. Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation? Cancer Immunology and Immunotherapy. 60: 1669-1681. doi: 10.1007/s00262-011-1118-z
- 2011. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncology Reports. 25: 1549-1556. doi: 10.3892/or.2011.1229
- 2011. Human cellular immune response against giardia lamblia 5 years after acute giardiasis. Journal of Infectious Diseases. 204: 1779-1786. doi: 10.1093/infdis/jir639
- 2011. Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology. 16: 351-356. doi: 10.1179/102453311X13127324303434
- 2011. Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukemia. Journal of Proteomics. 74: 269-281. doi: 10.1016/j.jprot.2010.11.003
- 2011. The chemokine system. in allogeneic stem-cell transplantation: a possible therapeutic target? Expert Review of Hematology. 4: 563-576. doi: 10.1586/EHM.11.54
- 2011. Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. Journal of Biomedicine and Biotechnology. 23 pages. doi: 10.1155/2011/104631
- 2011. Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer Journal. 1. doi: 10.1038/bcj.2011.2
- 2010. Minor diurnal and activity-induced variations in daytime peripheral blood platelet counts do not have any major impact on platelet yield by platelet apheresis. Transfusion and apheresis science. 43: 33-36. doi: 10.1016/j.transci.2010.05.005
- 2010. Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods. Transfusion. 50: 766-775. doi: 10.1111/j.1537-2995.2009.02540.x
- 2010. Platelet transfusion in acute leukemia patients with severe chemotherapy-induced thrombocytopenia: the possible importance of hemoglobin levels and red blood cell transfusions for evaluation of clinical effects of transfusion. Transfusion. 50: 2505-2506.
- 2010. Antivascular combo therapy: up-and-coming. Blood. 116: 1389-1390.
- 2010. The chemokine system in experimental and clinical hematology. Current Topics in Microbiology and Immunology. 341: 3-12. doi: 10.1007/82_2010_18
- 2010. Heat shock protein 90 (HSP90) inhibition-From experimental to clinical studies. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 34: 1422-1423. doi: 10.1016/j.leukres.2010.06.022
- 2010. Therapeutic targeting of NF-kappa B in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity. Expert opinion on therapeutic targets. 14: 1139-1142. doi: 10.1517/14728222.2010.525021
- 2010. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunology. 11. doi: 10.1186/1471-2172-11-38
- 2010. Connexin expression by human primary AML cells. Blood. 116: 887-887.
- 2010. Connexin-based signaling in acute myelogenous leukemia (AML). Biochimica et Biophysica Acta - Biomembranes. 1798: 1-8. doi: 10.1016/j.bbamem.2009.10.014
- 2010. Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - a report of five cases. Hematology. 15: 338-343. doi: 10.1179/102453310X12647083620967
- 2010. PRIMARY HUMAN AML CELLS CAN EXPRESS CALRETICULIN ON THE CELL SURFACE AND RELEASE HEAT SHOCK PROTEIN 70 (HSP70) AND HSP90 DURING APOPTOSIS. Haematologica. 95: 496-497.
- 2010. PRIMARY HUMAN ACUTE MYELOGENOUS LEUKEMIA CELLS RELEASE HEAT SHOCK PROTEIN (HSP) 70 AND HSP90 DURING APOPTOSIS. Experimental Hematology. 38: S19-S20.
- 2010. Clinical proteomics of myeloid leukemia. Genome Medicine. 2.
- 2010. Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005). Apoptosis (London). 15: 946-955. doi: 10.1007/s10495-010-0507-7
- 2010. OXYGEN LEVELS INFLUENCE THE CYTOKINE RELEASE PROFILE OF AML CELLS. Experimental Hematology. 38: S119-S119.
- 2010. Hypoxia increases HIF-1 alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. European Cytokine Network. 21: 154-164. doi: 10.1684/ecn.2010.0204
- 2010. The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia. Current Medicinal Chemistry. 17: 4448-4461.
- 2010. Clinical proteomics of myeloid leukemia. Genomu Igaku : Genome Medicine. 2. doi: 10.1186/gm162
- 2010. The Chemokine Network in Acute Myelogenous Leukemia: Molecular Mechanisms Involved in Leukemogenesis and Therapeutic Implications. Current Topics in Microbiology and Immunology. 341: 149-172. doi: 10.1007/82_2010_25
- 2010. Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological Experience. Journal of Biomedicine and Biotechnology. 15 pages. doi: 10.1155/2010/692097
- 2010. Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease. European Cytokine Network. 21: 40-49. doi: 10.1684/ecn.2009.0181
- 2010. Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia. Nutrition and Cancer. 62: 574-583. doi: 10.1080/01635580903532416
- 2010. PHARMACOLOGICAL TARGETING OF THE PI3K-AKT/PKB-MTOR PATHWAY ALTERS LOCAL ANGIOREGULATION IN ACUTE MYELOGENOUS LEUKEMIA. Haematologica. 95: 266-266.
- 2010. Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opinion on Investigational Drugs. 19: 169-183. doi: 10.1517/13543780903485659
- 2010. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. European Journal of Haematology. 84: 239-251. doi: 10.1111/j.1600-0609.2009.01382.x
- 2010. Circulating T Cells Derived From Patients with Low Risk Myelodysplastic Syndromes Show Altered Chemokine Receptor Expression. Blood. 116: 1637-1638.
- 2010. Combined epigenetic and signal transduction therapy modulate specific signal transduction patterns in acute myeloid leukemia. Haematologica. 95: 510-510.
- 2009. Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators. Cytotherapy. 11: 749-760. doi: 10.3109/14653240902980443
- 2009. Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells. Transfusion. 49: 354-361. doi: 10.1111/j.1537-2995.2008.01949.x
- 2009. Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods. Transfusion. Published 2009-12-18. doi: 10.1111/j.1537-2995.2009.02540.x
- 2009. Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report. Hematology. 14: 224-226. doi: 10.1179/102453309X439782
- 2009. Connexins Are Active Participants of Hematopoietic Stem Cell Regulation. Stem Cells and Development. 18: 807-812.
- 2009. Connexins are active participants of hematopoietic stem cell regulation. Stem Cells and Development. 18: 807-812. doi: 10.1089/scd.2009.0086
- 2009. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 144: 53-68. doi: 10.1111/j.1365-2141.2008.07411.x
- 2009. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. British Journal of Haematology. 144: 53-68. doi: 10.1111/j.1365-2141.2008.07411.x
- 2009. Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells. Transfusion. 49: 1709-1719. doi: 10.1111/j.1537-2995.2009.02180.x
- 2009. The protein kinase C agonist PEP005 increases NF-kB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology. 145: 761-774. doi: 10.1111/j.1365-2141.2009.07691.x
- 2009. The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia. Balkan Union of Oncology. Journal. 14: S131-S140.
- 2009. Granulocyttransfusjon. Tidsskrift for Den norske legeforening. 129: 416-419. doi: 10.4045/tidsskr.09.34313
- 2009. Heat shock protein 90-a potential target in the treatment of human acute myelogenous leukemia. Current Cancer Drug Targets. 9: 761-776.
- 2009. PRIMARY HUMAN ACUTE MYELOGENOUS LEUKEMIA CELLS SHOW CONSTITUTIVE RELEASE OF SEVERAL MATRIX METALLOPROTEASES AND THEIR INHIBITORS. Haematologica. 94: 545-545.
- 2009. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors; release profile and pharmacological modulaion. European Journal of Haematology. 84: 239-251. doi: 10.1111/j.1600-0609.2009.01382.x
- 2009. Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. Critical reviews in oncogenesis. 15: 1-41.
- 2009. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 33: 779-787. doi: 10.1016/j.leukres.2008.10.005
- 2009. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opinion on Investigational Drugs. 18: 433-455. doi: 10.1517/14728220902787628
- 2009. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer. 9. doi: 10.1186/1471-2407-9-77
- 2008. Anticancer Immunotherapy in Combination with Proapoptotic Therapy. Current Cancer Drug Targets. 8: 666-675. doi: 10.2174/156800908786733496
- 2008. Platelet functions and clinical effects in acute myelogenous leukemia. Thrombosis and Haemostasis. 99: 27-37. doi: 10.1160/TH07-04-0240
- 2008. Platelet functions and clinical effects in acute myelogenous leukemia. Thrombosis and Haemostasis. 99: 27-37.
- 2008. Platelet-released supernatants enhance hematopoietic stem cell proliferation in vitro. Platelets. 19: 155-159.
- 2008. Platelet-released supernatants enhance hematopoietic stem cell proliferation in vitro. Platelets. 19: 55-159. doi: 10.1080/09537100701767288
- 2008. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 111: 2866-2877. doi: 10.1182/blood-2007-07-103242
- 2008. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia. 22: 287-293. doi: 10.1038/sj.leu.2404985
- 2008. Effects of benzene on human hematopoiesis. The Open Hematology Journal. 2: 87-102. doi: 10.2174/1874276900802010087
- 2008. Review: genetic models of acute myeloid leukaemia. Oncogene. 27: 3765-3779. doi: 10.1038/onc.2008.16
- 2008. Evaluation of combinational therapy of MDM2-antagonist nutlin-3 and HDAC-inhibitor valproic acid in acute myeloid leukemia in vitro and in vivo. Blood. 112: 1024-1024.
- 2008. Chemokine receptor expression by circulating T cells derived from acute leukemia patients with severe chemotherapy-induced cytopenia express a wide range of chemokine receptors. Haematologica. 93: 456-457.
- 2008. Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors. Hematology. 13: 329-332. doi: 10.1179/102453308X343491
- 2008. In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22. Journal of Interferon and Cytokine Research. 28: 297-310. doi: 10.1089/jir.2007.0052
- 2008. In vivo biological effects of ATRA in the treatment of AML. Expert Opinion on Investigational Drugs. 17: 1623-1633. doi: 10.1517/13543780802440136
- 2008. FLT3 internal tandem duplication involving its libiquitin dependent endocytosis motif suspend modulation by HDM2 and are associated with inferior survival in AML. Haematologica. 93: 10-10.
- 2007. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion. 47: 653-665. doi: 10.1111/j.1537-2995.2007.01167.x
- 2007. Introduction: RNA and the treatment of human cancer. Current Pharmaceutical Biotechnology. 7: 318-319. doi: 10.2174/138920107783018408
- 2007. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 92: 332-341.
- 2007. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Current Pharmaceutical Biotechnology. 8: 388-400. doi: 10.2174/138920107783018417
- 2007. T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunology and Immunotherapy. 56: 013-925. doi: 10.1007/s00262-006-0236-5
- 2007. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology. 12: 199-207. doi: 10.1080/10245330701255163
- 2007. The Immunological Dilemma: Cellular Innate and Adaptive Immune Response Versus Human Acute Myeloid Leukemia. The Open Hematology Journal. 1: 1-14. doi: 10.2174/1874276900701010001
- 2007. Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunology and Immunotherapy. 56: 13-24. doi: 10.1007/s00262-006-0159-1
- 2007. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology. 79: 210-225. doi: 10.1111/j.1600-0609.2007.00899.x
- 2007. Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert opinion on therapeutic targets. 11: 1055-1069. doi: 10.1517/14728222.11.8.1055
- 2007. Release of angiopoietin-1 by acute myelogenous leukemia (AML) cells is increased by stromal cells and associated with mutations in the nucleophosmin (NPM) gene. Experimental Hematology. 35: 72-72.
- 2007. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Molecular Cancer. 6. doi: 10.1186/1476-4598-6-31
- 2007. Flt3 Y591 duplication and Bc1-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood. 109: 2589-2596. doi: 10.1182/blood-2006-02-004234
- 2007. In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts: The chemokine release profile of the AML dendritic cells depends on the experimental protocol. Haematologica. 92: 485-485.
- 2007. The protein kinase C activator PEP005 increases the chemokine release in native acute myelogenous leukemia (AML) blasts. Experimental Hematology. 35: 87-87.
- 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 366: 46-58. doi: 10.1016/j.ab.2007.03.013
- 2007. Epigenetic targeting in acute myeloid leukemia: use of flow cytometry in monitoring therapeutic effects. Current Pharmaceutical Biotechnology. 8: 401-411. doi: 10.2174/138920107783018462
- 2007. Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 31: 1303-1313. doi: 10.1016/j.leukres.2007.01.019
- 2007. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology. 136: 814-828. doi: 10.1111/j.1365-2141.2007.06504.x
- 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukamia cells indentify patient subgroups that differ susceptibility to histone deactylase inhibitors. International Journal of Oncology. 31: 1529-1538.
- 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. Haematologica. 92: 112-112.
- 2007. Linking susceptibility to histone deactylase inhibitors and basal gene expression profiles in acute myeloid leukaemia. Experimental Hematology. 35: 77-77.
- 2007. Flt3 mutations in proximity to an ubiquitin dependent endocytosis motif suspend its Hdm2 modulation. Blood. 110: 148B-148B.
- 2007. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Molecular Cancer. 6. doi: 10.1186/1476-4598-6-33
- 2007. Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Review of Anticancer Therapy. 7: 741-751. doi: 10.1586/14737140.7.5.741
- 2007. Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 8: 344-354. doi: 10.2174/138920107783018435
- 2006. Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion. 46: 800-810. doi: Se sammendragsfelt
- 2006. Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinformatics. 7: 198. doi: 10.1186/1471-2105-7-198
- 2006. Immunotherapy in chronic lymphocytic leukemia. Cancer Immunology and Immunotherapy. 55: 185-187. doi: 10.1007/s00262-005-0031-8
- 2006. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert opinion on therapeutic targets. 10: 51-68. doi: 10.1517/14728222.10.1.51
- 2006. Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia? Cancer Immunology and Immunotherapy. 55: 221-228. doi: 10.1007/s00262-005-0032-7
- 2006. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. International Journal of Cancer. 119: 2313-2321. doi: 10.1002/ijc.22180
- 2006. T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunology and Immunotherapy. 55: 830-840. doi: 10.1007/s00262-005-0080-z
- 2006. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy. Platelets. 17: 296-302. doi: 10.1080/09537100600746508
- 2006. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 30: 1531-1540.
- 2006. Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia. Acta Oncologica. 45: 346-349. doi: 10.1080/02841860500482233
- 2006. Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report. Leukemia. 20: 734-736. doi: 1038/sj.leu.2404117
- 2006. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clinical Cancer Research. 12: 3985-3992. doi: 10.1158/1078-0432.CCR-05-1970
- 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. International Journal of Oncology. 28: 1065-1080.
- 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. NBS-nytt. 1: 106.
- 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. International Journal of Molecular Medicine. 18: S65. Published 2006-10-13.
- 2005. Large-volume leukapheresis yields more viable CD34+cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+cells. Transfusion. 45: 248-253.
- 2005. Serum levels of angioregulatory mediators in healthy individuals depend on age and physical activity: studies of angiogenin, basic fibroblast growth factor, leptin and endostatin. Scandinavian Journal of Clinical and Laboratory Investigation. 65: 505-511. doi: 10.1080/00365510500209306
- 2005. In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum. Journal of Cancer Research and Clinical Oncology. 131: 377-384. doi: 10.1007/s00432-004-0650-z
- 2005. Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels. European Journal of Haematology. 74: 24-34.
- 2005. Antiangiogenic therapy in acute myelogenous leukemia: Targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets. 5: 229-248.
- 2005. The viability of cryopreserved PBPC depends on the DMSO concentration and the concentration of nucleated cells in the graft. Cytotherapy. 7: 328-333. doi: 10.1080/14653240500238251
- 2005. Animal models of acute myelogenous leukaemia - development, application and future perspectives. Leukemia. 19: 687-706. doi: 10.1038/sj.leu.2403670
- 2005. In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 29: 185-196. doi: 10.1016/j.leukres.2004.06.008
- 2005. Proteomics in acute myelogenous leukaemia (AML): Methodological strategies-and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 6: 631-646. doi: 10.2174/1389450054863671
- 2005. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 6: 631-646. doi: 10.2174/1389450054863671
- 2005. CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry. 64B: 18-27. doi: 10.1002/cyto.b.20044
- 2004. Better preservation of early hematopoietic progenitor cells when human peripheral blood progenitor cells are cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent dimethylsulfoxide. Transfusion. 44: 785-789.
- 2004. Autologous transplantation: the viable transplanted CD34(+) cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34(+) cell dose measured pre-freeze in patients that receive more than 2 x 10(6) CD34(+) cells/kg. Cytotherapy. 6: 356-362.
- 2004. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica. 89: 391-402.
- 2004. Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts. European Journal of Haematology. 73: 340-350.
- 2004. Characterization of ribosomal P autoantibodies in relation to cell destruction and autoimmune disease. Scandinavian Journal of Immunology. 60: 189-198. doi: 10.1111/j.0300-9475.2004.01450.x
- 2004. How should clinical data be included in experimental studies of cancer immunology? Cancer Immunology and Immunotherapy. 53: 677-680.
- 2004. In vitro effects of native human acute myelogenous leukemia blasts on fibroblasts and osteoblasts. International Journal of Cancer. 111: 858-867.
- 2004. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 118: 217-228.
- 2004. Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 28: 461-468.
- 2004. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia. Cancer Immunology and Immunotherapy. 53: 740-747.
- 2003. No differences in colony formation of peripheral blood stem cells frozen with 5% or 10% dimethyl sulfoxide. Journal of Hematotherapy & Stem Cell Research. 12: 351-358.
- 2003. Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts. European Journal of Haematology. 71: 9-17.
- 2003. In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 27: 455-464.
- 2003. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Studies in Surface Science and Catalysis. 4: 416-428.
- 2003. Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells. Cancer Immunology and Immunotherapy. 52: 215-225.
- 2003. The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status. European Journal of Haematology. 71: 163-173.
- 2003. Characterization of clonogenic progenitors in autologous peripheral blood stem cell grafts: evaluation of a simple in vitro assay suitable for routine clinical use. Hematology. 8: 313-318.
- 2003. Modified fatty acids and their possible therapeutic targets in malingnant diseases. Expert Opin. Ther. Targets. 7: 663-677.
- 2003. Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay. Journal of Hematotherapy & Stem Cell Research. 12: 525-535.
- 2002. Cryopreserving human peripheral blood progenitor cells with 5-percent rather than 10-percent DMSO results in less apoptosis and necrosis in CD34+ cells. Transfusion. 42: 1573-1580.
- 2002. Flow cytometric measurement of apoptosis and necrosis in cryopreserved PBPC concentrates from patients with malignant diseases. Bone Marrow Transplantation. 29: 165-171.
- 2002. Expression of Fc(epsilon)-receptors by human acute myelogenous leukemia (AML) blasts: studies of high- and low- (CD23) affinity receptor expression and the effects of IgE-mediated receptor ligation on functional AML blast characteristics. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 26: 515-521.
- 2002. A critical review of T cell targeting immunotherapy in pancreatic cancer: only a hypothesis or a real hope for the patients? Expert Opinion on Biological Therapy. 2: 693-701.
- 2002. Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells. Expert Opinion on Biological Therapy. 2: 197-210.
- 2002. Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemia blasts. Haematologica. 87: 584-595.
- 2002. Effects of cytarabine and various anthracyclins on platelet activation: characterization of in vitro effects and their possible clinical relevance in acute myelogenous leukemia. International Journal of Cancer. 97: 106-114.
- 2002. Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses. Journal of Hematotherapy & Stem Cell Research. 11: 469-481.
- 2002. Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. International Journal of Cancer. 101: 86-94.
- 2002. Acute myelogenous leukemia with internal tandem duplication of the Flt3 gene appearing or altering at the time of relapse: a report of two cases. Leukemia and Lymphoma. 43: 2027-2029.
- 2002. Circadian variations do not have a major impact on serum levels of soluble (S) L-selectin (CD63L), S-intercellular adhesion molecule 1 (sICAM-1/CD54) and thrombopoietin in healthy individuals. Scandinavian Journal of Clinical and Laboratory Investigation. 62: 75-79.
- 2002. Antiproliferative effects of a non-beta-oxidizable fatty acid, tetradecylthioacetic acid, in native human acute myelogenous leukemia blast cultures. Leukemia. 16: 2292-2301.
- 2002. Interleukin-7 (IL-7) in patients receiving intensive chemotherapy for acute myelogenous leukemia: studies of systemic IL-7 Levels and IL-7 responsiveness of circulating T lymphocytes. Journal of Interferon and Cytokine Research. 22: 1057-1065.
- 2001. Effects of azoles on human acute myelogenous leukemia blasts and T lymphocytes derived from acute leukemia patients with chemotherapy-induced cytopenia. International Immunopharmacology. 1: 2183-2195.
- 2001. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: Studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L). European Cytokine Network. 12: 231-238.
- 2001. New strategies in the treatment of acute myelogenous leukemia (AML): In vitro culture of AML cells: The present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells. 19: 1-11.
- 2001. Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? Expert Opinion on Biological Therapy. 1: 1005-1016.
- 2001. Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. European Journal of Haematology. 66: 365-376.
- 2001. Peripheral blood progenitor cell grafts contain high levels of platelet-secreted mediators. Transfusion. 41: 1431-1437.
- 2001. Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts. Journal of Hematotherapy & Stem Cell Research. 10: 81-93.
More information in national current research information system (CRIStin)